BiVictriX Therapeutics plc – Intention to float on AIM
August 02nd, 2021
BiVictriX Therapeutics plc, the developer of targeted cancer therapies based on its novel Bi-Cygni® approach, announces its intention to apply for admission to trading on AIM a market operated by the London Stock Exchange plc.
Related Stories
Head office
Copyright: BiVictriX Therapeutics plc 2023.
All Rights Reserved. Design & Development By Online Web Studio